Atorvastatin Therapy for Atherosclerotic Cardiovascular Disease

High‑Intensity Statin Initiation (Adults ≤ 75 y)

The American College of Cardiology recommends initiating high‑intensity statin therapy (atorvastatin 80 mg daily or rosuvastatin 20 mg daily) in all adults ≤ 75 years with clinical atherosclerotic cardiovascular disease (ASCVD). [@1]

For patients > 75 years with clinical ASCVD, a moderate‑intensity statin (e.g., atorvastatin 10–20 mg) is advised rather than high‑intensity therapy, because trials showed ASCVD event reduction with moderate intensity but no additional benefit from higher doses. [@1]

In ACS patients, initiating atorvastatin 80 mg daily at hospital admission reduced the composite cardiovascular endpoint by ≈ 16% compared with pravastatin 40 mg (p < 0.005). [@2]
The same high‑dose regimen (atorvastatin 80 mg daily) should be started immediately upon hospitalization for ACS, as endorsed by recent pharmacotherapy guidelines. [@2, @3, @6]

The American College of Cardiology advises starting atorvastatin 40–80 mg daily immediately in patients with established ASCVD, aiming for LDL‑C < 55 mg/dL (1.4 mmol/L) in very‑high‑risk individuals. [@1, @6]
If LDL‑C target is not reached after 4–6 weeks, add ezetimibe; if still uncontrolled after another 4–6 weeks, add a PCSK9 inhibitor. [@6]

For adults aged 40–75 years with a 10‑year ASCVD risk ≥ 10 %, moderate‑intensity statin therapy (atorvastatin 10–20 mg) is recommended; high‑intensity dosing (atorvastatin 40–80 mg) may be used for higher risk. [@4]
In primary‑prevention cohorts, low‑ to moderate‑dose statins reduce:
- all‑cause mortality by ≈ 14% (RR 0.86)
- cardiovascular mortality by ≈ 31% (RR 0.69)
- ischemic stroke by ≈ 29% (RR 0.71)
- myocardial infarction by ≈ 36% (RR 0.64)

In patients with a prior stroke or TIA, atorvastatin 80 mg daily lowered recurrent stroke risk by ≈ 16% (adjusted HR 0.84) and yielded an absolute risk reduction of 2.2 % over 5 years (SPARCL trial). [@5]
Major cardiovascular events were reduced by ≈ 20% (HR 0.80) with an absolute risk reduction of 3.5 % over 5 years. [@5]
However, hemorrhagic stroke occurred more frequently with atorvastatin (55 events) than with placebo (33 events). [@5]

Myopathy and rhabdomyolysis rates are low (≈ 0.1%) and comparable across atorvastatin doses. [@5]